Read by QxMD icon Read

Collaborative drug therapy agreement

Angela W Yaniv, Adam Orsborn, Joseph J Bonkowski, Lita Chew, Irene Krämer, Samuel Calabrese, Maria de la Paz Pacheco Ramos, Alessandro Palombi, Siew Woon Lim, Osama Tabbara, Carla Masini, Rudolf Schierl, Celestino Bufarini, Nate Peaty, Demis Paolucci
PURPOSE: The development of recommendations for advancing automated i.v. medication compounding is described. SUMMARY: Managing the shift from manual to robotic compounding of i.v. therapies requires an awareness of how automation affects practice and how to best implement robotics into current practice. An international panel of pharmacy professionals, researchers, and technology leaders with experience in i.v. robotics collaborated during a two-day meeting in August 2014 to define a general set of principles to broaden the understanding of the fundamental elements of robotic compounding worldwide...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
Brandon Battis, Linda Clifford, Mostaqul Huq, Edrick Pejoro, Scott Mambourg
OBJECTIVES: Patients treated with oral chemotherapy appear to have less contact with the treating providers. As a result, safety, adherence, medication therapy monitoring, and timely follow-up may be compromised. The trend of treating cancer with oral chemotherapy agents is on the rise. However, standard clinical guidance is still lacking for prescribing, monitoring, patient education, and follow-up of patients on oral chemotherapy across the healthcare settings. The purpose of this project is to establish an oral chemotherapy monitoring clinic, to create drug and lab specific provider order sets for prescribing and lab monitoring, and ultimately to ensure safe and effective treatment of the veterans we serve...
October 12, 2016: Journal of Oncology Pharmacy Practice
Stéphanie Sidorkiewicz, Viet-Thi Tran, Cécile Cousyn, Elodie Perrodeau, Philippe Ravaud
PURPOSE: Among patients on long-term medical therapy, we compared (1) patient and physician assessments of drug adherence and of drug importance and (2) drug adherence reported by patients with drug importance as assessed by their physicians. METHODS: We recruited to the study patients receiving at least 1 long-term drug treatment from both hospital and ambulatory settings in France. We compared drug adherence reported by patients and drug importance assessed by physicians using Spearman correlation coefficients...
September 2016: Annals of Family Medicine
Brittany A Todd, Donald G Lamprecht, Sheila L Stadler
PURPOSE: Prescribing practices within a clinical pharmacy cardiac risk service (CPCRS) and their impact on treatment outcomes in patients with atherosclerotic cardiovascular disease (ASCVD) are described. SUMMARY: National healthcare reforms have increased the population of insured patients and placed increased demands on physicians and other providers. Pharmacists are well trained and positioned to aid in patient care by providing expertise in medication management and patient safety that can result in pharmacotherapy optimization and cost savings...
September 15, 2016: American Journal of Health-system Pharmacy: AJHP
Kathryn J Hammer, Eve M Segal, Laura Alwan, Shan Li, Amila M Patel, Melinda Tran, Helen M Marshall
PURPOSE: The use of a collaborative drug therapy agreement (CDTA) by oncology pharmacists in a comprehensive pain clinic is described. SUMMARY: Recognizing the complex clinical services required by patients with cancer, the Seattle Cancer Care Alliance began offering cancer pain management through a specialized pain service. Initially, the clinic was staffed by one attending physician; however, as the volume of patient referrals increased, the clinic expanded into an interprofessional team that includes physicians, advanced practice providers, nurses, and pharmacists...
September 15, 2016: American Journal of Health-system Pharmacy: AJHP
Roger Woolf, Amanda Locke, Catherine Potts
PURPOSE: Pharmacist prescribing as part of a collaborative drug therapy agreement (CDTA) within an integrated health system in Washington is described. SUMMARY: Virginia Mason Medical Center (VMMC) in Seattle, Washington, uses a team-based care model with broad-based CDTAs to provide quality patient care. The majority of patients are referred to the pharmacist after a diagnosis has been made and a clinical care plan has been started. The pharmacist manages the patient's care within his or her scope of practice as defined by state laws and further detailed by VMMC internal protocols...
September 15, 2016: American Journal of Health-system Pharmacy: AJHP
Fumiyuki Watanabe, Kuniko Shinohara, Akira Dobashi, Kenji Amagai, Kazuo Hara, Kaori Kurata, Hideo Iizima, Kiyoshi Shimakawa, Masahiko Shimada, Sakurako Abe, Keiji Takei, Miwako Kamei
This study built a protocol for drug therapy management (hereinafter "the protocol") that would enable continuous support from the decision making of smoking cessation therapy to the completion of therapy through the collaboration of physicians and community pharmacists, after which we evaluated whether the use of this protocol would be helpful to smoking cessation therapy. This study utilized the "On the Promotion of Team-Based Medical Care", a Notification by the Health Policy Bureau as one of the resources for judgment, and referred to collaborative drug therapy management (CDTM) in the United States...
2016: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
Joel Lexchin
OBJECTIVES: Priority reviews of new drug applications are resource intensive and drugs approved through this process have a greater likelihood of acquiring a serious safety warning compared to drugs approved through the standard process. Therefore, when Health Canada uses priority reviews, it is important that it accurately identifies products that represent a significant therapeutic advance. The purpose of this study is to compare Health Canada's use of priority reviews to therapeutic ratings from two independent organisations, the Patented Medicine Prices Review Board (PMPRB) and the French drug bulletin Prescrire International, over the period 1 January 1997-31 December 2012...
2015: BMJ Open
B Rup, M Pallardy, D Sikkema, T Albert, M Allez, P Broet, C Carini, P Creeke, J Davidson, N De Vries, D Finco, A Fogdell-Hahn, E Havrdova, A Hincelin-Mery, M C Holland, P E H Jensen, E C Jury, H Kirby, D Kramer, S Lacroix-Desmazes, J Legrand, E Maggi, B Maillère, X Mariette, C Mauri, V Mikol, D Mulleman, J Oldenburg, G Paintaud, C R Pedersen, N Ruperto, R Seitz, S Spindeldreher, F Deisenhammer
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to advancing treatment in multiple disease areas, including inflammatory and autoimmune diseases, genetic deficiencies and cancer. Unfortunately, unwanted immunogenic responses to BPs, in particular those affecting clinical safety or efficacy, remain among the most common negative effects associated with this important class of drugs. To manage and reduce risk of unwanted immunogenicity, diverse communities of clinicians, pharmaceutical industry and academic scientists are involved in: interpretation and management of clinical and biological outcomes of BP immunogenicity, improvement of methods for describing, predicting and mitigating immunogenicity risk and elucidation of underlying causes...
September 2015: Clinical and Experimental Immunology
Harold R Collard, Williamson Z Bradford, Vincent Cottin, Kevin R Flaherty, Talmadge E King, Gary G Koch, Martin Kolb, Fernando J Martinez, Bruce Montgomery, Ganesh Raghu, Luca Richeldi, Dan Rose, Athol U Wells, Kevin K Brown
The past decade has seen substantial progress in understanding the pathobiology, natural history, and clinical significance of idiopathic pulmonary fibrosis (IPF), culminating in the establishment of two effective medical therapies. Now seems an important time to reconsider the design and conduct of future IPF clinical trials. Building on lessons learned over the past decade, we use this perspective to lay out four key considerations for moving forward effectively and efficiently with the next generation of clinical trials in IPF...
July 2015: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
Sarah E McBane, Anna L Dopp, Andrew Abe, Sandra Benavides, Elizabeth A Chester, Dave L Dixon, Michaelia Dunn, Melissa D Johnson, Sarah J Nigro, Tracie Rothrock-Christian, Amy H Schwartz, Kim Thrasher, Scot Walker
The American College of Clinical Pharmacy (ACCP) previously published position statements on collaborative drug therapy management (CDTM) in 1997 and 2003. Since 2003, significant federal and state legislation addressing CDTM has evolved and expanded throughout the United States. CDTM is well suited to facilitate the delivery of comprehensive medication management (CMM) by clinical pharmacists. CMM, defined by ACCP as a core component of the standards of practice for clinical pharmacists, is designed to optimize medication-related outcomes in collaborative practice environments...
April 2015: Pharmacotherapy
Margie E Snyder, Tara R Earl, Siobhan Gilchrist, Michael Greenberg, Holly Heisler, Michelle Revels, Dyann Matson-Koffman
Collaborative drug therapy management agreements are a strategy for expanding the role of pharmacists in team-based care with other providers. However, these agreements have not been widely implemented. This study describes the features of existing provider-pharmacist collaborative drug therapy management practices and identifies the facilitators and barriers to implementing such services in community settings. We conducted in-depth, qualitative interviews in 2012 in a federally qualified health center, an independent pharmacy, and a retail pharmacy chain...
2015: Preventing Chronic Disease
Cynthia Priyadarshini Gopal, Asri Ranga, Kevin Louis Joseph, Balamurugan Tangiisuran
INTRODUCTION: Although heart failure (HF) management is available at primary and secondary care facilities in Malaysia, the optimisation of drug therapy is still suboptimal. Although pharmacists can help bridge the gap in optimising HF therapy, pharmacists in Malaysia currently do not manage and titrate HF pharmacotherapy. The aim of this study was to develop treatment algorithms and monitoring protocols for angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and spironolactone based on extensive literature review for validation and utilization by pharmacists involved in HF management...
April 2015: Singapore Medical Journal
Elizabeth A Hansen, John M Pietkiewicz, Bonnie L Blum
Collaborative drug therapy management (CDTM) is a practice agreement between a pharmacist and a physician, which allows the pharmacist to assume responsibility of drug therapy management. There has been limited documentation of CDTM practices in the oncology setting. Therefore, a CDTM program in the gynecology oncology clinic at Roswell Park Cancer Institute (RPCI) was initiated to establish the feasibility and utility of CDTM and its effects on patient care and physician satisfaction. Primarily, 3 symptoms were managed by the CDTM pharmacists, namely chemotherapy-induced nausea and vomiting (CINV), chemotherapy-induced peripheral neuropathy (CIPN), and women's health...
June 2016: Journal of Pharmacy Practice
Christopher S Wisniewski, Sophie Robert, Sarah Ball
PURPOSE: The collaboration between a drug information center (DIC) and an academic detailing program is described. METHODS: An agreement was reached between the South Carolina Offering Prescribing Excellence (SCORxE) academic detailing program and the Medical University of South Carolina (MUSC) Drug Information Center (DIC) to provide responses to drug information (DI) questions pharmacists received on academic detailing visits. Questions received were analyzed to determine the impact that the collaboration had on MUSC DIC requests...
January 15, 2014: American Journal of Health-system Pharmacy: AJHP
Nicholas G Gottardo, Jordan R Hansford, Jacqueline P McGlade, Frank Alvaro, David M Ashley, Simon Bailey, David L Baker, Franck Bourdeaut, Yoon-Jae Cho, Moira Clay, Steven C Clifford, Richard J Cohn, Catherine H Cole, Peter B Dallas, Peter Downie, François Doz, David W Ellison, Raelene Endersby, Paul G Fisher, Timothy Hassall, John A Heath, Hilary L Hii, David T W Jones, Reimar Junckerstorff, Stewart Kellie, Marcel Kool, Rishi S Kotecha, Peter Lichter, Stephen J Laughton, Sharon Lee, Geoff McCowage, Paul A Northcott, James M Olson, Roger J Packer, Stefan M Pfister, Torsten Pietsch, Barry Pizer, Scott L Pomeroy, Marc Remke, Giles W Robinson, Stefan Rutkowski, Tobias Schoep, Anang A Shelat, Clinton F Stewart, Michael Sullivan, Michael D Taylor, Brandon Wainwright, Thomas Walwyn, William A Weiss, Dan Williamson, Amar Gajjar
Medulloblastoma is curable in approximately 70% of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4...
February 2014: Acta Neuropathologica
Derick Anderson
Patient care within the US healthcare system is changing constantly, as are the roles of healthcare practitioners, including pharmacists. For over 30 years, pharmacists have promoted the concept of clinical pharmacy, which places pharmacists in a central role in patient medication management. The goal is to allow the pharmacist to become a vital part of treatment planning by individualizing patients' therapeutic regimens. The Collaborative Drug Therapy Management agreement is a step toward that goal. The combination of drug therapy management and compounding pharmacy can be powerful in meeting patients' specific needs...
January 2007: International Journal of Pharmaceutical Compounding
Hélène Blons, Etienne Rouleau, Nathanaël Charrier, Gilles Chatellier, Jean-François Côté, Jean-Christophe Pages, Florence de Fraipont, Jean-Christophe Boyer, Jean Philippe Merlio, Alain Morel, Marie-Claude Gorisse, Patricia de Cremoux, Karen Leroy, Gérard Milano, L'houcine Ouafik, Jean-Louis Merlin, Delphine Le Corre, Pascaline Aucouturier, Jean-Christophe Sabourin, Frédérique Nowak, Thierry Frebourg, Jean-François Emile, Isabelle Durand-Zaleski, Pierre Laurent-Puig
PURPOSE: Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the French National Cancer Institute (INCa) has set up a national network of 28 regional molecular genetics centers...
2013: PloS One
Steven R Levine, Pooja Khatri, Joseph P Broderick, James C Grotta, Scott E Kasner, Doojin Kim, Brett C Meyer, Peter Panagos, Jose Romano, Phillip Scott
BACKGROUND AND PURPOSE: Since Food and Drug Administration approval of intravenous tissue-type plasminogen activator (tPA) for treatment of acute ischemic stroke in 1996, it has become clear that several criteria used for exclusion from therapy were not based on actual data or operationally defined for use in clinical practice. All eligibility criteria from the National Institute of Neurological Disorders and Stroke (NINDS) recombinant tPA Stroke Study were adopted within the alteplase package insert as contraindications/warnings...
September 2013: Stroke; a Journal of Cerebral Circulation
Dolores Gallardo-Rincón, David Cantú-de-León, Patricia Alanís-López, Miguel Angel Alvarez-Avitia, Joel Bañuelos-Flores, Guillermo Sidney Herbert-Núñez, Luis Fernando Oñate-Ocaña, María Delia Pérez-Montiel, Amelia Rodríguez-Trejo, Eva Ruvalcaba-Limón, Alberto Serrano-Olvera, Andrea Ortega-Rojo, Patricia Cortés-Esteban, Aura Erazo-Valle, Raquel Gerson-Cwilich, Jaime De-la-Garza-Salazar, Dan Green-Renner, Eucario León-Rodríguez, Flavia Morales-Vásquez, Andrés Poveda-Velasco, José Luis Aguilar-Ponce, Luis Felipe Alva-López, Salvador Alvarado-Aguilar, Isabel Alvarado-Cabrero, Cinthia Alejandra Aquino-Mendoza, Carlos Eduardo Aranda-Flores, Artfy Bandera-Delgado, Eduardo Barragán-Curiel, Patricia Barrón-Rodríguez, Rocío Brom-Valladares, Paula Anel Cabrera-Galeana, Germán Calderillo-Ruiz, Salvador Camacho-Gutiérrez, Daniel Capdeville-García, Jesús Cárdenas-Sánchez, Elisa Carlón-Zárate, Oscar Carrillo-Garibaldi, Gerardo Castorena-Roji, Guadalupe Cervantes-Sánchez, Jaime Alberto Coronel-Martínez, José Gregorio Chanona-Vilchis, Verónica Díaz-Hernández, Pedro Escudero-de-los Ríos, Olga Garibay-Cerdenares, Eva Gómez-García, Luis Alonso Herrera-Montalvo, Luz María Hinojosa-García, David Isla-Ortiz, Josefina Jiménez-López, Arturo Javier Lavín-Lozano, Jesús Alberto Limón-Rodriguez, Horacio Noé López-Basave, Sergio César López-García, Antonio Maffuz-Aziz, Jorge Martínez-Cedillo, Dulce María Martínez-López, Juan Manuel Medina-Castro, Carlos Melo-Martínez, Carmen Méndez-Herrera, Gonzalo Montalvo-Esquivel, Miguel Angel Morales-Palomares, Andrés Morán-Mendoza, Gilberto Morgan-Villela, Aída Mota-García, David Eduardo Muñoz-González, Francisco J Ochoa-Carrillo, Maricruz Pérez-Amador, Edgar Recinos-Money, Samuel Rivera-Rivera, Juan U Robles Flores, Edith Rojas-Castillo, Carlos Rojas-Marín, Efraín Salas-Gonzáles, Liliana Sámano-Nateras, Miguel Santibañez-Andrade, Antonio Santillán-Gómez, Araceli Silva-García, Juan Alejandro Silva, Gilberto Solorza-Luna, Adán Raúl Tabarez-Ortiz, Patricia Talamás-Rohana, Laura Leticia Tirado-Gómez, Alfonso Torres-Lobatón, Félix Quijano-Castro
INTRODUCTION: Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia...
November 2011: Revista de Investigación Clínica; Organo del Hospital de Enfermedades de la Nutrición
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"